7. References


  • [1] A. Elshaug, ‘Appropriate Use Criteria’, 2016.

  • [2] M. R. U. Department of Health Australia, ‘MBS data’, 2016.

  • [3] A. B. of Statistics, ‘Australian Demographic Statistics’, 3101.0 - Australian Demographic statistics Jun 2010 and Jun 2015. [Online]. Available: http://www.abs.gov.au/ausstats/abs@.nsf/Previousproducts/3101.0Main Features1Jun 2015?opendocument&tabname=Summary&prodno=3101.0&issue=Jun 2015&num=&view=. [Accessed: 25-Apr-2016].

  • [4] R. S. Bahn, H. B. Burch, D. S. Cooper, R. S. Bahn, H. B. Burch, and D. S. Cooper, ‘ATA / AACE Guidelines HYPERTHYROIDISM AND OTHER CAUSES OF THYROTOXICOSIS: MANAGEMENT GUIDELINES OF THE AMERICAN THYROID ASSOCIATION AND AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS HYPERTHYROIDISM AND OTHER CAUSES OF THYROTOXICOSIS : MANAGEMENT GUID’, vol. 17, no. 3, pp. 1–65, 2011.

  • [5] K. L. Snook, P. L. H. Stalberg, S. B. Sidhu, M. S. Sywak, P. Edhouse, and L. Delbridge, ‘Recurrence after total thyroidectomy for benign multinodular goiter.’, World J. Surg., vol. 31, no. 3, pp. 593–8; discussion 599–600, Mar. 2007.

  • [6] M. R. U. Department of Health, ‘MBS data’.

  • [7] B. R. Haugen, E. K. Alexander, K. C. Bible, G. M. Doherty, S. J. Mandel, Y. E. Nikiforov, F. Pacini, G. W. Randolph, A. M. Sawka, M. Schlumberger, K. G. Schuff, S. I. Sherman, J. A. Sosa, D. L. Steward, R. M. Tuttle, and L. Wartofsky, ‘2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.’, Thyroid, vol. 26, no. 1, pp. 1–133, Jan. 2016.

  • [8] M. R. U. Department of Health Australia, ‘MBS data - Cognos’, 2016.

  • [9] O. Norlén, K. C. Wang, Y. K. Tay, W. R. Johnson, S. Grodski, M. Yeung, J. Serpell, S. Sidhu, M. Sywak, and L. Delbridge, ‘No need to abandon focused parathyroidectomy: a multicenter study of long-term outcome after surgery for primary hyperparathyroidism.’, Ann. Surg., vol. 261, no. 5, pp. 991–6, May 2015.

  • [10] J. Norman, J. Lopez, and D. Politz, ‘Abandoning unilateral parathyroidectomy: why we reversed our position after 15,000 parathyroid operations.’, J. Am. Coll. Surg., vol. 214, no. 3, pp. 260–9, 2012.

  • [11] A. Chitale, P. Musonda, A. M. McGregor, and K. K. Dhatariya, ‘Determining the utility of the 60 min cortisol measurement in the short synacthen test.’, Clin. Endocrinol. (Oxf)., vol. 79, no. 1, pp. 14–9, Jul. 2013.

  • [12] C. P. Woods, N. Argese, M. Chapman, C. Boot, R. Webster, V. Dabhi, A. B. Grossman, A. A. Toogood, W. Arlt, P. M. Stewart, R. K. Crowley, and J. W. Tomlinson, ‘Adrenal suppression in patients taking inhaled glucocorticoids is highly prevalent and management can be guided by morning cortisol’, Eur. J. Endocrinol., vol. 173, no. 5, pp. 633–642, 2015.

  • [13] W. J. Inder and P. J. Hunt, ‘Glucocorticoid replacement in pituitary surgery: guidelines for perioperative assessment and management.’, J. Clin. Endocrinol. Metab., vol. 87, no. 6, pp. 2745–50, Jun. 2002.

  • [14] T. Deutschbein, N. Unger, K. Mann, and S. Petersenn, ‘Diagnosis of secondary adrenal insufficiency in patients with hypothalamic-pituitary disease: Comparison between serum and salivary cortisol during the high-dose short synacthen test’, Eur. J. Endocrinol., vol. 160, no. 1, pp. 9–16, Jan. 2009.

  • [15] W. S. Yo, L.-M. Toh, S. J. Brown, W. D. Howe, D. E. Henley, and E. M. Lim, ‘How good is a morning cortisol in predicting an adequate response to intramuscular synacthen stimulation?’, Clin. Endocrinol. (Oxf)., vol. 81, no. 1, pp. 19–24, Jul. 2014.

  • [16] C. W. Le Roux, K. Meeran, and J. Alaghband-Zadeh, ‘Is a 0900-h serum cortisol useful prior to a short synacthen test in outpatient assessment?’, Ann. Clin. Biochem., vol. 39, no. Pt 2, pp. 148–50, Mar. 2002.

  • [17] F. M. Gioacchini, M. Alicandri-Ciufelli, S. Kaleci, G. Magilulo, L. Presutti, and M. Re, ‘Clinical presentation and treatment outcomes of thyroglossal duct cysts: a systematic review’, Int. J. Oral Maxillofac. Surg., vol. 44, no. 1, pp. 119–26, 2015.

  • [18] M. R. U. Department of Health Australia, ‘MBS data - Q20320’, 2016.

  • [19] C. D. Adkisson, G. M. Howell, K. L. McCoy, M. J. Armstrong, M. L. Kelley, M. T. Stang, J. M. Joyce, S. P. Hodak, S. E. Carty, and L. Yip, ‘Surgeon volume and adequacy of thyroidectomy for differentiated thyroid cancer’, Surgery, vol. 156, no. 6, pp. 1453–1460, Dec. 2014.

  • [20] M. M. Chowdhury, H. Dagash, and A. Pierro, ‘A systematic review of the impact of volume of surgery and specialization on patient outcome’, British Journal of Surgery, vol. 94, no. 2. pp. 145–161, Feb-2007.

  • [21] A. Duclos, J.-L. Peix, C. Colin, J.-L. Kraimps, F. Menegaux, F. Pattou, F. Sebag, S. Touzet, S. Bourdy, N. Voirin, and J.-C. Lifante, ‘Influence of experience on performance of individual surgeons in thyroid surgery: prospective cross sectional multicentre study’, BMJ, vol. 344, no. jan10 2, pp. d8041–d8041, Jan. 2012.

  • [22] M. A. Adam, S. Thomas, L. Youngwirth, T. Hyslop, S. D. Reed, R. P. Scheri, S. A. Roman, and J. A. Sosa, ‘Is There a Minimum Number of Thyroidectomies a Surgeon Should Perform to Optimize Patient Outcomes?’, Ann. Surg., Mar. 2016.

  • [23] J. W. Serpell, J. C. Lee, M. J. Yeung, S. Grodski, W. Johnson, and M. Bailey, ‘Differential recurrent laryngeal nerve palsy rates after thyroidectomy’, Surg. (United States), vol. 156, no. 5, pp. 1157–1166, 2014.

  • [24] J. Lee, S. Fraser, A. Glover, and S. Sidhu, ‘Prospective evaluation of the utility of routine neuromonitoring for an established thyroid surgical practice.’, ANZ J. Surg., Apr. 2016.



|

_________________________________________